S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)
S&P 500   4,970.64 (-0.81%)
DOW   37,853.71 (+0.21%)
QQQ   416.58 (-1.61%)
AAPL   164.51 (-1.51%)
MSFT   399.91 (-1.08%)
META   483.86 (-3.58%)
GOOGL   153.76 (-1.44%)
AMZN   175.28 (-2.20%)
TSLA   149.19 (-0.49%)
NVDA   807.88 (-4.59%)
AMD   148.19 (-4.44%)
NIO   3.83 (-4.25%)
BABA   68.60 (-0.41%)
T   16.35 (+0.12%)
F   12.10 (+0.33%)
MU   107.31 (-4.13%)
GE   149.30 (-2.38%)
CGC   8.04 (+2.68%)
DIS   111.60 (-0.74%)
AMC   3.22 (+10.27%)
PFE   25.84 (+1.77%)
PYPL   61.92 (-0.29%)
XOM   120.03 (+1.27%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.17
+0.9%
$1.15
$0.98
$1.89
$36.57M-0.6866,385 shs4,638 shs
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$63.29
+1.1%
$65.06
$44.27
$74.64
$1.42B0.87111,658 shs29,749 shs
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
$13.16
+1.1%
$13.78
$9.57
$21.60
$492.32M1.04406,416 shs90,764 shs
Surmodics, Inc. stock logo
SRDX
Surmodics
$26.57
+0.7%
$29.54
$16.79
$39.41
$378.36M1.0157,361 shs13,856 shs
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
+1.75%-6.45%+5.45%-4.92%-22.15%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
-0.67%-4.63%-6.63%+8.62%+19.05%
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
+0.15%-6.67%-6.20%-3.63%-30.45%
Surmodics, Inc. stock logo
SRDX
Surmodics
-0.49%-4.66%-5.04%-22.31%+12.11%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.7393 of 5 stars
3.02.00.04.40.60.00.6
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
3.1804 of 5 stars
1.33.04.20.02.33.32.5
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
0.5962 of 5 stars
2.01.00.00.01.71.71.3
Surmodics, Inc. stock logo
SRDX
Surmodics
4.1234 of 5 stars
3.52.00.03.42.31.71.9

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50113.68% Upside
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
2.67
Moderate Buy$68.207.76% Upside
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
2.00
Hold$15.5017.78% Upside
Surmodics, Inc. stock logo
SRDX
Surmodics
3.00
Buy$59.00122.05% Upside

Current Analyst Ratings

Latest SRDX, CODX, LMAT, and OFIX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/10/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$47.00
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
3/7/2024
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
Roth Mkm
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$12.00 ➝ $15.00
2/28/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Barrington Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$66.00 ➝ $69.00
2/6/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
KeyCorp
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Weight
2/1/2024
Surmodics, Inc. stock logo
SRDX
Surmodics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$44.00 ➝ $47.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.37N/AN/A$2.81 per share0.42
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$193.48M7.34$1.79 per share35.30$13.38 per share4.73
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
$746.64M0.66N/AN/A$16.11 per share0.82
Surmodics, Inc. stock logo
SRDX
Surmodics
$132.58M2.85$0.79 per share33.82$8.48 per share3.13

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Estimated)
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$30.10M$1.3447.2334.772.7215.56%10.57%9.15%5/7/2024 (Estimated)
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
-$151.40M-$4.14N/AN/AN/A-20.28%-10.63%-7.34%5/14/2024 (Estimated)
Surmodics, Inc. stock logo
SRDX
Surmodics
-$1.54M$0.3869.92N/AN/A3.99%8.06%5.11%4/24/2024 (Estimated)

Latest SRDX, CODX, LMAT, and OFIX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/5/2024Q4 2023
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
-$0.60-$0.59+$0.01-$0.59N/A$200.42 million    
2/27/2024Q4 2023
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.36$0.38+$0.02$0.38$49.01 million$48.90 million    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
$0.641.01%+13.80%47.76%13 Years
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
N/AN/AN/AN/AN/A
Surmodics, Inc. stock logo
SRDX
Surmodics
N/AN/AN/AN/AN/A

Latest SRDX, CODX, LMAT, and OFIX Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/21/2024
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
Quarterly$0.160.9%3/13/20243/14/20243/28/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
N/A
6.51
4.57
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
0.19
2.54
1.20
Surmodics, Inc. stock logo
SRDX
Surmodics
0.24
4.84
3.97

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
84.64%
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
89.76%
Surmodics, Inc. stock logo
SRDX
Surmodics
96.63%

Insider Ownership

CompanyInsider Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.40%
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
12.40%
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
4.70%
Surmodics, Inc. stock logo
SRDX
Surmodics
8.90%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
LeMaitre Vascular, Inc. stock logo
LMAT
LeMaitre Vascular
61422.45 million19.54 millionOptionable
Orthofix Medical Inc. stock logo
OFIX
Orthofix Medical
1,63437.41 million35.65 millionOptionable
Surmodics, Inc. stock logo
SRDX
Surmodics
37614.24 million12.97 millionOptionable

SRDX, CODX, LMAT, and OFIX Headlines

SourceHeadline
Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1Surmodics to Report Second Quarter of Fiscal 2024 Financial Results on May 1
businesswire.com - April 19 at 7:00 AM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
finance.yahoo.com - April 17 at 2:18 PM
Will SurModics (SRDX) Report Negative Q2 Earnings? What You Should KnowWill SurModics (SRDX) Report Negative Q2 Earnings? What You Should Know
zacks.com - April 17 at 11:06 AM
Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"Surmodics (NASDAQ:SRDX) Upgraded by StockNews.com to "Strong-Buy"
americanbankingnews.com - April 17 at 3:42 AM
Surmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.comSurmodics (NASDAQ:SRDX) Rating Increased to Strong-Buy at StockNews.com
marketbeat.com - April 16 at 11:04 PM
Investors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three yearsInvestors in Surmodics (NASDAQ:SRDX) have unfortunately lost 54% over the last three years
finance.yahoo.com - April 13 at 8:40 AM
Surmodics, Inc. to Post Q1 2025 Earnings of ($0.23) Per Share, Zacks Research Forecasts (NASDAQ:SRDX)Surmodics, Inc. to Post Q1 2025 Earnings of ($0.23) Per Share, Zacks Research Forecasts (NASDAQ:SRDX)
americanbankingnews.com - April 12 at 2:20 AM
Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)Q1 2025 Earnings Estimate for Surmodics, Inc. Issued By Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 11 at 7:42 AM
Surmodics (SRDX) Buy Rating Reiterated at Needham & Company LLCSurmodics' (SRDX) Buy Rating Reiterated at Needham & Company LLC
americanbankingnews.com - April 11 at 5:24 AM
Surmodics, Inc. Expected to Earn Q4 2025 Earnings of $0.66 Per Share (NASDAQ:SRDX)Surmodics, Inc. Expected to Earn Q4 2025 Earnings of $0.66 Per Share (NASDAQ:SRDX)
americanbankingnews.com - April 11 at 1:48 AM
Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)Analysts Offer Insights on Healthcare Companies: Genprex (GNPX) and SurModics (SRDX)
markets.businessinsider.com - April 10 at 4:59 PM
Surmodics (SRDX) "Buy" Rating Reiterated at Needham & Company LLCSurmodics' (SRDX) "Buy" Rating Reiterated at Needham & Company LLC
marketbeat.com - April 10 at 11:26 AM
Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)Q4 2025 EPS Estimates for Surmodics, Inc. Boosted by Zacks Research (NASDAQ:SRDX)
marketbeat.com - April 10 at 8:44 AM
New Strong Buy Stocks for April 9thNew Strong Buy Stocks for April 9th
zacks.com - April 9 at 7:16 AM
Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?Should You Think About Buying Surmodics, Inc. (NASDAQ:SRDX) Now?
finance.yahoo.com - March 23 at 1:09 PM
Q2 2024 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by AnalystQ2 2024 EPS Estimates for Surmodics, Inc. (NASDAQ:SRDX) Reduced by Analyst
marketbeat.com - March 22 at 7:50 AM
Brokers Offer Predictions for Surmodics, Inc.s Q4 2025 Earnings (NASDAQ:SRDX)Brokers Offer Predictions for Surmodics, Inc.'s Q4 2025 Earnings (NASDAQ:SRDX)
marketbeat.com - March 21 at 8:36 AM
Heres Why You Should Hold Surmodics (SRDX) Stock for NowHere's Why You Should Hold Surmodics (SRDX) Stock for Now
zacks.com - March 20 at 12:30 PM
Are Surmodics, Inc.s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?Are Surmodics, Inc.'s (NASDAQ:SRDX) Mixed Financials Driving The Negative Sentiment?
finance.yahoo.com - March 2 at 1:31 PM
Surmodics to Participate in Upcoming Investor Conferences in March and AprilSurmodics to Participate in Upcoming Investor Conferences in March and April
businesswire.com - February 27 at 8:00 AM
SYK Jun 2024 290.000 putSYK Jun 2024 290.000 put
ca.finance.yahoo.com - February 6 at 1:03 PM
Heres What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter ResultsHere's What Analysts Are Forecasting For Surmodics, Inc. (NASDAQ:SRDX) After Its First-Quarter Results
finance.yahoo.com - February 4 at 9:23 AM
Heres Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.s (NASDAQ:SRDX) CEO Pay PacketHere's Why Shareholders May Want To Be Cautious With Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Pay Packet
finance.yahoo.com - February 2 at 5:33 PM
Surmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call TranscriptSurmodics, Inc. (NASDAQ:SRDX) Q1 2024 Earnings Call Transcript
finance.yahoo.com - February 2 at 12:26 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
LeMaitre Vascular logo

LeMaitre Vascular

NASDAQ:LMAT
LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. The company also provides artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches, used for closure of vessels after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; cardiovascular patches; carotid shunts that temporarily shunt the blood to the brain during the removal of plaque in a carotid endarterectomy surgery; biosynthetic vascular graft indicated for lower extremity bypass and dialysis access; and vascular grafts used to bypass or replace diseased arteries. In addition, it offers radiopaque tape, a medical-grade tape applied to the skin that enables surgeons and interventionalists to cross-refer between the inside and the outside of a patient's body and allows them to locate tributaries or lesions beneath the skin. Further, the company provides valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.
Orthofix Medical logo

Orthofix Medical

NASDAQ:OFIX
Orthofix Medical Inc. operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions. This segment also designs, develops, and markets a portfolio of navigation technologies, including tracked surgical tools, intelligent software, and imaging equipment based on machine-vision and optical innovations. The Global Orthopedics segment offers products and solutions that allow physicians to treat various orthopedic conditions related to limb reconstruction and deformity correction unrelated to the spine. This segment designs, develops, and markets external and internal fixation orthopedic products that are coupled with enabling digital technologies to serve the complete patient treatment pathway. It sells its products through distributors and sales representatives to hospitals, healthcare organizations, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1980 and is headquartered in Lewisville, Texas.
Surmodics logo

Surmodics

NASDAQ:SRDX
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths. The IVD segment develops, manufactures, and sells chemical and biological components for in vitro diagnostic immunoassay and molecular tests, as well as diagnostic and biomedical research markets. This segment offers protein stabilizers, substrates, surface coatings, and antigens. The company was founded in 1979 and is headquartered in Eden Prairie, Minnesota.